From Nasdaq: 2025-06-09 19:40:00

Lipocine Inc. (LPCN) and its licensing partner, Verity Pharma, have submitted a New Drug Submission (NDS) for TLANDO, the FDA-approved oral testosterone replacement therapy, in Canada. CEO Mahesh Patel sees Canada as a promising market for TLANDO, with over 700,000 TRT prescriptions written annually in the country. If approved, TLANDO could have a significant impact due to its unique benefits. With minimal promotional efforts in the current TRT market, TLANDO has the potential to stand out. In January 2024, Lipocine granted Verity Pharma exclusive rights to commercialize TLANDO in the U.S. and Canada. LPCN is trading higher at $3.4031 on the Nasdaq Capital Market.



Read more at Nasdaq: Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine